Skip to content

5 Biotech Giants Snapped Up in Q1 2025: Who’s Next?

In the first quarter of 2025, the biotech industry witnessed a significant uptick in acquisition activity. Johnson & Johnson acquired Ambrx, Merck took over Harpoon, GSK purchased Aiolos, and Novartis bought Calypso, all in early January. By the end of the quarter, Gilead had also made a notable acquisition. These deals highlight a trend where large pharmaceutical companies are actively seeking to expand their portfolios through strategic acquisitions. The flurry of activity suggests a robust market for biotech mergers and acquisitions, with companies looking to bolster their pipelines with innovative therapies and technologies. This trend could signal potential growth opportunities for investors in the biotech sector, as companies with promising assets become prime targets for acquisition.

Source: seekingalpha.com

Related Videos